Agenus Inc.
NASDAQ:AGENBiotechnology
Healthcare
$6.14 -0.17%
-$0.01 today
- Market cap
- $277.81M
- Beta
- 1.54
- P/E (TTM)
- 1.7
- EPS (TTM)
- $1.70
52W Low $2.71High $7.34
Volume 0.82M
Average 0.82M
Income Statement
Follow revenue through to earnings.
Revenue
$114.20M
FY 2025 · Annual
+10.4% YoYOperating Income
-$20.56M
FY 2025 · Annual
Net Income
$115,000.00
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 295.67M | 98.02M | 156.31M | 103.46M | 114.2M |
| Cost of Revenue | 182.08M | 197.26M | 237.68M | 156.01M | 80.36M |
| Gross Profit | 113.59M | (99.24M) | (81.37M) | (52.55M) | 33.84M |
| Gross Margin | 38.4% | -101.2% | -52.1% | -50.8% | 29.6% |
| Research & Development | 178.61M | 0 | 234.57M | 155.53M | 0 |
| Selling, General & Admin | 76.36M | 81.01M | 78.74M | 71.88M | 54.39M |
| Operating Expenses | 87.84M | 80.19M | 78.18M | 67.92M | 54.39M |
| Depreciation & Amortization | 6.79M | 6.95M | 13.59M | 13.34M | 10M |
| EBITDA | 43.78M | (161.85M) | (145.92M) | (101.3M) | 62.19M |
| EBITDA Margin | 14.8% | -165.1% | -93.4% | -97.9% | 54.5% |
| Operating Income | 25.75M | (179.43M) | (159.55M) | (120.48M) | (20.56M) |
| Operating Margin | 8.7% | -183.0% | -102.1% | -116.4% | -18.0% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 65.72M | 61.86M | 97.93M | 117.63M | 55.27M |
| Other Income / Expenses | (54.47M) | (51.23M) | (97.89M) | (111.8M) | 17.47M |
| Income Before Tax | (28.72M) | (230.66M) | (257.44M) | (232.27M) | (3.08M) |
| Pre-Tax Margin | -9.7% | -235.3% | -164.7% | -224.5% | -2.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (23.93M) | (220.07M) | (245.76M) | (227.21M) | 115K |
| Net Margin | -8.1% | -224.5% | -157.2% | -219.6% | 0.1% |
| EPS (Basic) | (2.11) | (15.64) | (13.75) | (10.59) | (0.00) |
| EPS (Diluted) | (2.11) | (15.64) | (13.75) | (10.59) | (0.00) |
| 11.45M | 14.09M | 17.89M | 21.47M | 29.73M | |
| 11.45M | 14.09M | 17.89M | 21.47M | 29.73M |
AGEN Earnings Waterfall · TTM
NASDAQ:AGEN · Revenue to Net Income
Key Ratios
EPS$1.66
Gross Margin47.8%
Net Margin47.0%
P/E Ratio-0.6
P/S Ratio4.0
Analysis
$123.9M of revenue converted into $64.6M of net income for the selected period. Gross margin is 47.8% and net margin is 47.0%, showing how much revenue survives after costs and taxes. EPS is $1.66, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 2, 2026 |
How much revenue does AGEN generate?
Agenus Inc. (AGEN) reported $114.20M of revenue in fiscal 2025.
Is AGEN profitable?
Agenus Inc. (AGEN) reported $115,000.00 of net income, with a net margin of 0.1%.
Continue the stock analysis
Jump to another research area for this company.